Delcath Systems, Inc. Announces Executive Changes, Effective on June 1, 2020
May 23, 2020 at 01:37 am IST
Share
Delcath Systems, Inc. announced that on May 18, 2020, Jennifer K. Simpson submitted her resignation as the Chief Executive Officer of the company. Ms. Simpson's resignation of her employment as the Chief Executive Officer of the Company, to be effective on June 1, 2020, was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On May 20, 2020, the Board of Directors of the Company appointed John Purpura, M.S., the Company's Executive Vice President, Global Head Operations, to serve as the Interim Chief Executive Officer of the company, effective on June 1, 2020, until such time as the Company appoints a successor Chief Executive Officer.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
DELCATH SYSTEMS, INC. 
